Trials / Available
AvailableNCT03015844
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Northwell Health · Academic / Other
- Sex
- All
- Age
- 365 Days – 29 Years
- Healthy volunteers
- —
Summary
This is an expanded access protocol/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Response rate, toxicity, and time to progression and death will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 131-I-meta-iodobenzylguanidine |
Timeline
- First posted
- 2017-01-10
- Last updated
- 2024-07-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03015844. Inclusion in this directory is not an endorsement.